ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RGNT vs CLGN // NET PROFIT MARGIN

Regentis Biomaterials Ltd. (NYSE) VS. CollPlant Biotechnologies Ltd (NASDAQ) • 15-METRIC TALLY: RGNT 0 — CLGN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGNT VS. CLGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RGNT CLGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 64.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -14.39% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 CLGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.2 56.3 -18.11 CLGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $9.6M $12.7M -$3.1M CLGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RGNT REV CLGN REV RGNT GROSS % CLGN GROSS % RGNT FCF CLGN FCF
FY 2025 $0 $2.4M — 64.8% -$1.4M -$9.4M
FY 2024 $0 $515.0K — -50.0% -$641.0K -$14.6M
FY 2023 $0 $11.0M — — -$1.2M -$2.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGNT // BETA —
CLGN // BETA —